BioSpace News Archive

Business

Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis

After the regulator rejected avasopasem manganese, its candidate for severe oral mucositis, Galera is implementing a restructuring initiative that involves reducing its headcount by 70%.

August 10, 2023
·
2 min read
·
Tristan Manalac
Business

Illumina Lowers Outlook as Business Challenges, Exec Departures Continue

The company has lowered its 2023 guidance amid leadership changes and antitrust scrutiny. Illumina now expects a 1% increase in revenue, down from its previous 7% to 10% growth forecast.

August 10, 2023
·
2 min read
·
Tristan Manalac
Drug Development

J&J Snags FDA Approval for Second Multiple Myeloma Bispecific Antibody

Despite being heavily pretreated, patients on J&J’s Talvey saw a 73.6% overall response rate in a Phase II study, winning accelerated approval from the regulator.

August 10, 2023
·
2 min read
·
Kate Goodwin
Business

Novo Nordisk Boosts Obesity Business with $1B Inversago Buy

Amid record sales of its obesity treatment Wegovy, as well as diabetes drugs Ozempic and Rybelsus, Novo is buying Canadian biotech Inversago Pharma to further boost its weight-loss pipeline.

August 10, 2023
·
2 min read
·
Tristan Manalac
Drug Development

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

The FDA has four decisions on deck this week, including ones for two rare disease treatments from Ipsen and Regeneron.

August 10, 2023
·
5 min read
·
Tristan Manalac
Business

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.

August 10, 2023
·
8 min read
Innate Pharma to Participate in Upcoming Investor Conference - August 10, 2023

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conference.

August 10, 2023
·
3 min read
XNK Therapeutics enters into agreement with US-based biotechnology company

XNK Therapeutics AB announced that the company has entered into an agreement with a US biotechnology company.

August 10, 2023
·
2 min read
Drug Development

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Sosei Group Corporation and Cancer Research UK announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.

August 10, 2023
·
8 min read
Policy

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Limited announced that it has received an approval letter from the Nasdaq Stock Market LLC Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market.

August 10, 2023
·
3 min read